EUVIMEDEUVIMED entdecken
Open Access

Development and Validation of the American Heart Association’s PREVENT Equations

Sadiya S Khan iD, Kunihiro Matsushita iD, Yingying Sang iD, Shoshana H Ballew iD, Morgan E Grams iD, Aditya Surapaneni iD, Michael J Blaha iD, April P Carson iD, Alexander R Chang iD, Elizabeth Ciemins iD, Alan S Go iD, Orlando M Gutierrez iD und 16 weitere

Circulation · 06.02.2024 · 149 (6) · 430-449

DOI: 10.1161/circulationaha.123.067626 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 06.02.2024. Verfasst von Sadiya S Khan und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.S.K.). Hauptthemen laut MEDLINE: Cardiovascular Diseases, Heart Failure, Atherosclerosis. Die Arbeit wurde bisher 1345-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Multivariable equations are recommended by primary prevention guidelines to assess absolute risk of cardiovascular disease (CVD). However, current equations have several limitations. Therefore, we developed and validated the American Heart Association Predicting Risk of CVD EVENTs (PREVENT) equations among US adults 30 to 79 years of age without known CVD. METHODS: The derivation sample included individual-level participant data from 25 data sets (N=3 281 919) between 1992 and 2017. The primary outcome was CVD (atherosclerotic CVD and heart failure). Predictors included traditional risk factors (smoking status, systolic blood pressure, cholesterol, antihypertensive or statin use, and diabetes) and estimated glomerular filtration rate. Models were sex-specific, race-free, developed on the age scale, and adjusted for competing risk of non-CVD death. Analyses were conducted in each data set and meta-analyzed. Discrimination was assessed using the Harrell C-statistic. Calibration was calculated as the slope of the observed versus predicted risk by decile. Additional equations to predict each CVD subtype (atherosclerotic CVD and heart failure) and include optional predictors (urine albumin-to-creatinine ratio and hemoglobin A1c), and social deprivation index were also developed. External validation was performed in 3 330 085 participants from 21 additional data sets. RESULTS: Among 6 612 004 adults included, mean±SD age was 53±12 years, and 56% were women. Over a mean±SD follow-up of 4.8±3.1 years, there were 211 515 incident total CVD events. The median C-statistics in external validation for CVD were 0.794 (interquartile interval, 0.763–0.809) in female and 0.757 (0.727–0.778) in male participants. The calibration slopes were 1.03 (interquartile interval, 0.81–1.16) and 0.94 (0.81–1.13) among female and male participants, respectively. Similar estimates for discrimination and calibration were observed for atherosclerotic CVD– and heart failure–specific models. The improvement in discrimination was small but statistically significant when urine albumin-to-creatinine ratio, hemoglobin A1c, and social deprivation index were added together to the base model to total CVD (ΔC-statistic [interquartile interval] 0.004 [0.004–0.005] and 0.005 [0.004–0.007] among female and male participants, respectively). Calibration improved significantly when the urine albumin-to-creatinine ratio was added to the base model among those with marked albuminuria (>300 mg/g; 1.05 [0.84–1.20] versus 1.39 [1.14–1.65]; P =0.01). CONCLUSIONS: PREVENT equations accurately and precisely predicted risk for incident CVD and CVD subtypes in a large, diverse, and contemporary sample of US adults by using routinely available clinical variables.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesHeart FailureAtherosclerosisAdultHumansMaleFemaleMiddle AgedAgedCreatinineGlycated HemoglobinAmerican Heart AssociationRisk FactorsAlbuminsRisk Assessment

Stichwörter der Autor:innen

cardiovascular diseasesheart failurekidney diseasesmodels, cardiovascularrisk assessmentsocial determinants of health

Substanzen

CreatinineGlycated HemoglobinAlbumins

Autor:innen und Institutionen

  • Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.S.K.).
  • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (K.M., Y.S., S.H.B., J.C.).
  • Department of Population Health, New York University Grossman School of Medicine, New York, NY (Y.S., S.H.B., J.C.).
  • Department of Medicine, Division of Precision Medicine, New York University Grossman School of Medicine, New York, NY (M.E.G., A.S.).
  • Johns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, Baltimore, MD (M.J.B.).
  • University of Mississippi Medical Center, Jackson (A.P.C.).

ORCID-Profile: Sadiya S Khan, Kunihiro Matsushita, Yingying Sang, Shoshana H Ballew, Morgan E Grams, Aditya Surapaneni, Michael J Blaha, April P Carson, Alexander R Chang, Elizabeth Ciemins, Alan S Go, Orlando M Gutierrez, Shih-Jen Hwang, Simerjot K Jassal, Donald M Lloyd-Jones, Michael G Shlipak, Latha P Palaniappan, Laurence Sperling, Salim S Virani, Katherine Tuttle, Ian J Neeland, Janani Rangaswami, Michael J Pencina, Chiadi E Ndumele, Josef Coresh

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NIGMS NIH HHS
  • NIH HHS
  • NCATS NIH HHS
  • NIMHD NIH HHS
  • HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
  • HHS | NIH | National Heart, Lung, and Blood Institute

Zitieren

APA

Khan, S. S., Matsushita, K., Sang, Y., Ballew, S. H., Grams, M. E., Surapaneni, A., Blaha, M. J., Carson, A. P., Chang, A. R., Ciemins, E., Go, A. S., Gutierrez, O. M., Hwang, S. J., Jassal, S. K., Kovesdy, C. P., Lloyd-Jones, D. M., Shlipak, M. G., Palaniappan, L. P., Sperling, L., …, & Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group (2024). Development and Validation of the American Heart Association’s PREVENT Equations. Circulation, 149(6), 430-449. https://doi.org/10.1161/circulationaha.123.067626

Vancouver

Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, et al. Development and Validation of the American Heart Association’s PREVENT Equations. Circulation. 2024;149(6):430-449. doi:10.1161/circulationaha.123.067626

BibTeX
@article{Khan2024,
  author = {Khan, Sadiya S and Matsushita, Kunihiro and Sang, Yingying and Ballew, Shoshana H and Grams, Morgan E and Surapaneni, Aditya and Blaha, Michael J and Carson, April P and Chang, Alexander R and Ciemins, Elizabeth and Go, Alan S and Gutierrez, Orlando M and Hwang, Shih-Jen and Jassal, Simerjot K and Kovesdy, Csaba P and Lloyd-Jones, Donald M and Shlipak, Michael G and Palaniappan, Latha P and Sperling, Laurence and Virani, Salim S and Tuttle, Katherine and Neeland, Ian J and Chow, Sheryl L and Rangaswami, Janani and Pencina, Michael J and Ndumele, Chiadi E and Coresh, Josef and Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group, Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group},
  title = {Development and Validation of the American Heart Association’s PREVENT Equations},
  journal = {Circulation},
  year = {2024},
  volume = {149},
  number = {6},
  pages = {430--449},
  doi = {10.1161/circulationaha.123.067626}
}
Kostenlos starten →